Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle

Background and methods Silica-coated magnetic nanoparticle (SiO2-MNP) prepared by the sol-gel method was studied as a nanocarrier for targeted delivery of tissue plasminogen activator (tPA). The nanocarrier consists of a superparamagnetic iron oxide core and an SiO2 shell and is characterized by transmission electron microscopy, Fourier transform infrared spectroscopy, X-ray diffraction, superconducting quantum interference device, and thermogravimetric analysis. An amine-terminated surface silanizing agent (3-aminopropyltrimethoxysilane) was used to functionalize the SiO2 surface, which provides abundant –NH2 functional groups for conjugating with tPA. Results The optimum drug loading is reached when 0.5 mg/mL tPA is conjugated with 5 mg SiO2-MNP where 94% tPA is attached to the carrier with 86% retention of amidolytic activity and full retention of fibrinolytic activity. In vitro biocompatibility determined by lactate dehydrogenase release and cell proliferation indicated that SiO2-MNP does not elicit cytotoxicity. Hematological analysis of blood samples withdrawn from mice after venous administration indicates that tPA-conjugated SiO2-MNP (SiO2-MNP-tPA) did not alter blood component concentrations. After conjugating to SiO2-MNP, tPA showed enhanced storage stability in buffer and operation stability in whole blood up to 9.5 and 2.8-fold, respectively. Effective thrombolysis with SiO2-MNP-tPA under magnetic guidance is demonstrated in an ex vivo thrombolysis model where 34% and 40% reductions in blood clot lysis time were observed compared with runs without magnetic targeting and with free tPA, respectively, using the same drug dosage. Enhanced penetration of SiO2-MNP-tPA into blood clots under magnetic guidance was confirmed from microcomputed tomography analysis. Conclusion Biocompatible SiO2-MNP developed in this study will be useful as a magnetic targeting drug carrier to improve clinical thrombolytic therapy.

[1]  Yan Deng,et al.  Preparation and biomedical applications of core-shell silica/magnetic nanoparticle composites. , 2012, Journal of nanoscience and nanotechnology.

[2]  N. Qiu,et al.  Affinity adsorption and separation behaviors of avidin on biofunctional magnetic nanoparticles binding to iminobiotin. , 2011, Colloids and surfaces. B, Biointerfaces.

[3]  Tommy Olsson,et al.  The use of magnetite nanoparticles for implant-assisted magnetic drug targeting in thrombolytic therapy. , 2010, Biomaterials.

[4]  T. Pellegrino,et al.  From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. , 2010, Pharmacological research.

[5]  O. McCarty,et al.  Rational Design of an Ex Vivo Model of Thrombosis , 2010 .

[6]  T. Hole,et al.  Early warning signs of an acute myocardial infarction and their influence on symptoms during the acute phase, with comparisons by gender. , 2009, Gender medicine.

[7]  Miqin Zhang,et al.  Multifunctional Magnetic Nanoparticles for Medical Imaging Applications. , 2009, Journal of materials chemistry.

[8]  D. Ferri,et al.  Chemical Availability and Reactivity of Functional Groups grafted to Magnetic Nanoparticles monitored In situ by ATR-IR Spectroscopy , 2009 .

[9]  Mu-Yi Hua,et al.  Magnetically targeted thrombolysis with recombinant tissue plasminogen activator bound to polyacrylic acid-coated nanoparticles. , 2009, Biomaterials.

[10]  Chang-Ha Lee,et al.  Immobilization of lipase on hydrophobic nano-sized magnetite particles , 2009 .

[11]  J. Alam,et al.  Iron oxide nanoparticles-chitosan composite based glucose biosensor. , 2008, Biosensors & bioelectronics.

[12]  A. Rosengart,et al.  Encapsulation and release of plasminogen activator from biodegradable magnetic microcarriers. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[13]  Jerry S. H. Lee,et al.  Magnetic nanoparticles in MR imaging and drug delivery. , 2008, Advanced drug delivery reviews.

[14]  J. Ni,et al.  The grafting and release behavior of doxorubincin from Fe3O4@SiO2 core–shell structure nanoparticles via an acid cleaving amide bond: the potential for magnetic targeting drug delivery , 2008, Nanotechnology.

[15]  Hongjuan Ma,et al.  Covalent-bonded immobilization of enzyme on hydrophilic polymer covering magnetic nanogels , 2008 .

[16]  Jianfeng Chen,et al.  Synthesis of Porous Magnetic Hollow Silica Nanospheres for Nanomedicine Application , 2007 .

[17]  Vladimir R Muzykantov,et al.  The Glycocalyx Protects Erythrocyte-Bound Tissue-Type Plasminogen Activator from Enzymatic Inhibition , 2007, Journal of Pharmacology and Experimental Therapeutics.

[18]  A. Rosengart,et al.  Physicochemical characteristics of magnetic microspheres containing tissue plasminogen activator , 2007 .

[19]  M. Jou,et al.  Effects of external magnetic field on biodistribution of nanoparticles: A histological study , 2007 .

[20]  Jing Sun,et al.  Synthesis and characterization of biocompatible Fe3O4 nanoparticles. , 2007, Journal of biomedical materials research. Part A.

[21]  L. Tamariz,et al.  Review of the Evidence on Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism , 2007, The Annals of Family Medicine.

[22]  G. Wang,et al.  Effects of the concentration of tetramethylammonium hydroxide peptizer on the synthesis of Fe3O4/SiO2 core/shell nanoparticles , 2006 .

[23]  Manuel Arruebo,et al.  Development of Magnetic Nanostructured Silica-Based Materials as Potential Vectors for Drug-Delivery Applications , 2006 .

[24]  Ajay Kumar Gupta,et al.  Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. , 2005, Biomaterials.

[25]  Jackie Y Ying,et al.  Silica-coated nanocomposites of magnetic nanoparticles and quantum dots. , 2005, Journal of the American Chemical Society.

[26]  Vladimir R Muzykantov,et al.  Blood Clearance and Activity of Erythrocyte-Coupled Fibrinolytics , 2005, Journal of Pharmacology and Experimental Therapeutics.

[27]  C. Barbé,et al.  Silica Particles: A Novel Drug‐Delivery System , 2004 .

[28]  G. Chow,et al.  Carboxyl group (–CO2H) functionalized ferrimagnetic iron oxide nanoparticles for potential bio-applications , 2004 .

[29]  Nathan Kohler,et al.  A bifunctional poly(ethylene glycol) silane immobilized on metallic oxide-based nanoparticles for conjugation with cell targeting agents. , 2004, Journal of the American Chemical Society.

[30]  C. Bárcena,et al.  APPLICATIONS OF MAGNETIC NANOPARTICLES IN BIOMEDICINE , 2003 .

[31]  S. Smye,et al.  A mathematical model of post-canalization thrombolysis. , 2002, Physics in medicine and biology.

[32]  Weihong Tan,et al.  Synthesis and Characterization of Silica-Coated Iron Oxide Nanoparticles in Microemulsion: The Effect of Nonionic Surfactants , 2001 .

[33]  S. Davis,et al.  Preparation of ultrafine silica- and PEG-coated magnetite particles , 2001 .

[34]  V. Yang,et al.  A novel heparin/protamine-based pro-drug type delivery system for protease drugs. , 2000, Journal of pharmaceutical sciences.

[35]  Peter Kopčanský,et al.  Immobilization of proteins and enzymes to fine magnetic particles , 1999 .

[36]  A. Maitra,et al.  Nanometer Silica Particles Encapsulating Active Compounds: A Novel Ceramic Drug Carrier , 1998 .

[37]  Goodhew.  The Basics of Crystallography and Diffraction , 1998 .

[38]  S L Diamond,et al.  Inner clot diffusion and permeation during fibrinolysis. , 1993, Biophysical journal.

[39]  H. Swaisgood,et al.  A spectrophotometric assay for solid phase primary amino groups , 1992 .

[40]  S. Yoshioka,et al.  Inactivation Kinetics of Enzyme Pharmaceuticals in Aqueous Solution , 1991, Pharmaceutical Research.

[41]  D. Botstein,et al.  High resolution analysis of functional determinants on human tissue-type plasminogen activator. , 1991, The Journal of biological chemistry.

[42]  E. Goldsmith,et al.  Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Mimuro.  [Type 1 plasminogen activator inhibitor]. , 1990, Rinsho byori. The Japanese journal of clinical pathology.

[44]  E A Trowbridge,et al.  The extension rate independence of the hysteresis in glutaraldehyde-fixed bovine pericardium. , 1987, Biomaterials.

[45]  D. T. Shiu,et al.  Activation of plasminogen by tissue plasminogen activator on normal and thrombasthenic platelets: effects on surface proteins and platelet aggregation. , 1986, Blood.

[46]  郑俊海,et al.  科技期刊稿件处理的精细化管理——《International Journal of Nanomedicine〉〉投稿体会 , 2014 .

[47]  M. Mahmoudi,et al.  Superparamagnetic iron oxide nanoparticles (SPIONs): development, surface modification and applications in chemotherapy. , 2011, Advanced drug delivery reviews.

[48]  Ashley J. Driscoll,et al.  Enzyme nanoparticle fabrication: magnetic nanoparticle synthesis and enzyme immobilization. , 2011, Methods in molecular biology.

[49]  Michael D Kaminski,et al.  Improvement of in vitro thrombolysis employing magnetically-guided microspheres. , 2008, Thrombosis research.

[50]  J. van Gijn,et al.  Clinical practice. Acute ischemic stroke. , 2007, The New England journal of medicine.

[51]  S. Diamond,et al.  Engineering design of optimal strategies for blood clot dissolution. , 1999, Annual review of biomedical engineering.

[52]  G. Goissis,et al.  Biocompatibility studies of anionic collagen membranes with different degree of glutaraldehyde cross-linking. , 1999, Biomaterials.

[53]  Albert P. Philipse,et al.  Magnetic silica dispersions: preparation and stability of surface-modified silica particles with a magnetic core , 1994 .

[54]  S. Holmberg.  Thrombolysis in acute myocardial infarction. , 1992, British journal of hospital medicine.

[55]  S. Pizzo,et al.  Preparation of polyethylene glycol-tissue plasminogen activator adducts that retain functional activity: characteristics and behavior in three animal species. , 1988, Blood.